Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy-Reference-Cited by-同舟云学术

Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy

Published:2024-07-20 Issue:8 Volume:63 Page:1089-1109
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Bayoumy Ahmed B.^ORCID,Ansari A. R.,Mulder C. J. J.,Schmiegelow K.,Florin Timothy,De Boer N. K. H.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01393-0.pdf

Reference84 articles.

1. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8(1):24–36. https://doi.org/10.1038/nrc2292.

2. Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, De Boer NK. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. Expert Opin Drug Metab Toxicol. 2020;16(2):111–23. https://doi.org/10.1080/17425255.2020.1719996.

3. Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genomics. 2010;20(9):573–4. https://doi.org/10.1097/FPC.0b013e328334338f.

4. Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK. Routinely established skewed thiopurine metabolism leads to a strikingly high rate of early therapeutic failure in patients with inflammatory bowel disease. Ther Drug Monit. 2015;37(6):797–804. https://doi.org/10.1097/ftd.0000000000000213.

5. Meijer B, Kreijne JE, van Moorsel SAW, et al. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2017;32(6):1183–90. https://doi.org/10.1111/jgh.13656.